GlassScriptPhysician profile
Nanjappa Sreenivas
NPI 1730101668
$7,703.42
in general payments reported to CMS, 2019-2025
20 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $459 · 2021: $885 · 2022: $1,441 · 2023: $1,632 · 2024: $1,908 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,751.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,639.85 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,176.79 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,101.48 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $936.12 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $731.88 | 2019-2025 | Rexulti |
| Alkermes, INC. | $448.11 | 2019-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $383.07 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $245.38 | 2019-2023 | Trintellix |
| Abbvie INC. | $202.97 | 2021-2023 | Vraylar |
| Idorsia Pharmaceuticals US INC | $177.18 | 2022-2024 | Quviviq |
| Indivior INC. | $147.59 | 2019-2023 | Perseris |
| Corium, LLC | $141.39 | 2023-2024 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $113.68 | 2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $74.64 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $55.84 | 2020-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $35.02 | 2023-2024 | Auvelity |
| Shire North American Group INC | $34.60 | 2019 | |
| Acadia Pharmaceuticals INC | $31.41 | 2019-2021 | |
| Allergan, INC. | $15.13 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanjappa Sreenivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.